

A skewed view of X chromosome inactivation

Jakub Minks, Wendy P. Robinson, Carolyn J. Brown

J Clin Invest. 2008;**118**(1):20-23. <https://doi.org/10.1172/JCI34470>.

Commentary

X chromosome inactivation involves a random choice to silence either X chromosome early in mammalian female development. Once silenced the inactive X is stably inherited through subsequent somatic cell divisions, and thus, females are generally mosaics, having a mixture of cells with one or the other parental X active. While in most females the number of cells with either X being active is roughly equal, skewing of X chromosome inactivation is observed in a percentage of women. In this issue of the *JCI*, Bolduc and colleagues address whether skewing of X chromosome inactivation in humans is influenced by an X-linked locus that can alter this initial random inactivation (see the related article beginning on page 333). Their data indicate that most of the skewing observed in humans results from secondary events rather than being due to an inherited tendency to inactivate a particular X chromosome.

Find the latest version:

<https://jci.me/34470/pdf>





(alanine or glycine) in the ATP-binding pocket (Figure 2). A series of ATP analogs (benzyl-ATP) possessing a side group to fit into the engineered hole have been generated. Only the analog-sensitive (as-) mutant, not the wild-type kinase, can efficiently use these ATP analogs as phosphate donors. Therefore, only unique substrates of the as-kinase are labeled by the ATP analogs. A modification of this approach that generates a thiophosphate ester at the phosphorylation site for detection with an antibody has been successfully used to identify direct substrates of as-kinases (18). In our view, an as- δ PKC mutant will be an important tool for identifying specific δ PKC substrates phosphorylated in response to ischemia and reperfusion, hypertension, and microvascular dysfunction. The δ PKC signaling pathways revealed during disease progression should facilitate the development of additional δ PKC-based therapeutic strategies.

Acknowledgments

This work was supported by NIH grant AA013588 and funds provided by the state of California for medical research on alcohol and substance abuse through the University of California at San Francisco (to

R.O. Messing) and by NIH grant NS057195 and UCSF REAC grant (to W.H. Chou).

Address correspondence to: Robert O. Messing, Ernest Gallo Clinic and Research Center at UCSF, 5858 Horton Street, Suite 200, Emeryville, California 94608, USA. Phone: (510) 985-3950; Fax: (510) 985-3101; E-mail: romes@gallo.ucsf.edu.

- Cecchelli, R., et al. 2007. Modelling of the blood-brain barrier in drug discovery and development. *Nat. Rev. Drug Discov.* **6**:650–661.
- Hawkins, B.T., and Davis, T.P. 2005. The blood-brain barrier/neurovascular unit in health and disease. *Pharmacol. Rev.* **57**:173–185.
- Mark, K.S., and Davis, T.P. 2002. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. *Am. J. Physiol. Heart Circ. Physiol.* **282**:H1485–H1494.
- Harhaj, N.S., and Antonetti, D.A. 2004. Regulation of tight junctions and loss of barrier function in pathophysiology. *Int. J. Biochem. Cell. Biol.* **36**:1206–1237.
- Abbott, N.J., Ronnback, L., and Hansson, E. 2006. Astrocyte-endothelial interactions at the blood-brain barrier. *Nat. Rev. Neurosci.* **7**:41–53.
- Blumenfeld, J.D., et al. 2001. Renin system activation and delayed function of the renal transplant. *Am. J. Hypertens.* **14**:1270–1272.
- Steinberg, S.F. 2004. Distinctive activation mechanisms and functions for protein kinase Cdelta. *Biochem. J.* **384**:449–459.
- Mochly-Rosen, D. 1995. Localization of protein kinases by anchoring proteins: a theme in signal transduction. *Science*. **268**:247–251.
- Schwarze, S.R., Ho, A., Vocero-Akbani, A., and

Dowdy, S.F. 1999. In vivo protein transduction: delivery of a biologically active protein into the mouse. *Science*. **285**:1569–1572.

- Qi, X., Inagaki, K., Sobel, R.A., and Mochly-Rosen, D. 2008. Sustained pharmacological inhibition of δ PKC protects against hypertensive encephalopathy through prevention of blood-brain barrier breakdown in rats. *J. Clin. Invest.* **118**:173–182.
- Chen, L., et al. 2001. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. *Proc. Natl. Acad. Sci. U. S. A.* **98**:11114–11119.
- Inagaki, K., et al. 2003. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. *Circulation*. **108**:2304–2307.
- Murriel, C.L., Churchill, E., Inagaki, K., Szewda, L.I., and Mochly-Rosen, D. 2004. Protein kinase Cdelta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria. *J. Biol. Chem.* **279**:47985–47991.
- Ikeno, F., Inagaki, K., Rezaee, M., and Mochly-Rosen, D. 2007. Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage. *Cardiovasc. Res.* **73**:699–709.
- Bright, R., et al. 2004. Protein kinase C delta mediates cerebral reperfusion injury in vivo. *J. Neurosci.* **24**:6880–6888.
- Bright, R., Steinberg, G.K., and Mochly-Rosen, D. 2007. DeltaPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo. *Brain Res.* **1144**:146–155.
- Shimohata, T., et al. 2007. Suppression of deltaPKC activation after focal cerebral ischemia contributes to the protective effect of hypothermia. *J. Cereb. Blood Flow Metab.* **27**:1463–1475.
- Allen, J.J., et al. 2007. A semisynthetic epitope for kinase substrates. *Nat. Methods*. **4**:511–516.

A skewed view of X chromosome inactivation

Jakub Minks, Wendy P. Robinson, and Carolyn J. Brown

Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

X chromosome inactivation involves a random choice to silence either X chromosome early in mammalian female development. Once silenced the inactive X is stably inherited through subsequent somatic cell divisions, and thus, females are generally mosaics, having a mixture of cells with one or the other parental X active. While in most females the number of cells with either X being active is roughly equal, skewing of X chromosome inactivation is observed in a percentage of women. In this issue of the JCI, Bolduc and colleagues address whether skewing of X chromosome inactivation in humans is influenced by an X-linked locus that can alter this initial random inactivation (see the related article beginning on page 333). Their data indicate that most of the skewing observed in humans results from secondary events rather than being due to an inherited tendency to inactivate a particular X chromosome.

Nonstandard abbreviations used: Xce, X chromosome controlling element; XCI, X chromosome inactivation; Xist, X (inactive)-specific transcript.

Conflict of interest: The authors have declared that no conflict of interest exists.


Citation for this article: *J. Clin. Invest.* **118**:20–23 (2008). doi:10.1172/JCI34470.

What is skewed X chromosome inactivation?

X chromosome inactivation (XCI) — a process originally hypothesized by Lyon in 1961 (1) and by which one of the two copies of the X chromosome present in females is inactivated — achieves dosage

equivalency for X-linked genes between XY males and XX females. A critical tenet of this hypothesis was that the initial choice of which X (maternal or paternal) to inactivate was random but then this choice was stably inherited. An individual cell's decision to inactivate either the paternal or maternal X is made early in development, at approximately the time of implantation (2). A deviation from equal (50%) inactivation of each parental allele is known as skewing, with common criteria for "skewed" inactivation being arbitrarily defined as the observation of inactivation of the same allele in 75% or 80% of cells (and very skewed inactivation resulting in 90% or 95% of cells with the same allele inactive).

A solid understanding of the causes of skewed XCI is needed because skewing is often used as a tool in the clinical setting

**Figure 1**

Skewed XCI in females. **(A)** Skewed XCI can result from either a primary nonrandom inactivation or a secondary, acquired nonrandom inactivation. There are two active X chromosomes in the female embryo, one from each parent (maternal and paternal; X^m and X^p, respectively). Upon inactivation, one X forms the heterochromatic inactive X depicted here as a darkly staining oval. The cells are shaded to reflect the different origins of their remaining active X. Subsequent stochastic or selective growth of one cell population leads to skewing of inactivation. However, if the initial inactivation was influenced by an allele (analogous to the murine *Xce* allele) then inactivation could be directed primarily towards one allele. A reduction in the embryonic precursor pool size at the time of random choice would make skewed XCI more likely. **(B)** The common way to examine XCI skewing makes use of a highly polymorphic CAG repeat (shown here as having allele sizes a and b) in the androgen receptor gene and differential methylation (methylation shown as black lollipop while the unmethylated allele has open lollipops) of the active (X^a) and inactive (Xⁱ) X. DNA is extracted from the cells to be tested and then digested with a methylation-sensitive restriction enzyme (shown as scissors). The methylated (Xⁱ) DNA will remain intact for subsequent PCR amplification using primers (shown as arrows) flanking the cut site. The ratio of the alleles (a and b, distinguished by PCR product length) in the undigested compared with the digested DNA reflects the XCI skewing.

(see *The clinical relevance of skewed XCI*). As shown in Figure 1A, some individuals will undergo skewed XCI by chance, as there is a limited pool of cells at the time of inactivation and only a limited precursor population that contributes to any tissue. Selection can also lead to a secondary (or acquired) skewed inactivation. In addition, there may be variants controlling the initial choice of which X to inactivate, resulting in primary nonrandom inactivation. For example, in mice there is a locus known as the X chromosome controlling element (*Xce*) that differs between strains and results in primary skewing of inactivation during animal crosses (3). The murine *Xce* is located downstream of X (inactive)-specific transcript (*Xist*) (4), a gene that codes for a non-protein coding RNA that localizes to the inactive X chromosome and has been shown to be

sufficient for XCI (reviewed in ref. 5). Whether there is a similar locus involved in XCI skewing in humans remains an open question. In this issue of the *JCI*, the study by Bolduc et al. addresses the relative contribution to XCI skewing of primary and secondary influences by investigating skewing in a population of over 500 pairs of healthy female mothers and their neonates (6).

Assays to examine XCI skewing require the presence of a polymorphism to distinguish the two Xs and a means of determining which X is active. While examining RNA or protein is a more direct measure of X chromosome activity, DNA methylation of the inactive X is often used as a surrogate since DNA is more easily extracted, stored, and analyzed. Furthermore, coding region polymorphisms are generally less informative and can show

allelic imbalances in expression levels. An assay monitoring DNA methylation of the highly polymorphic CAG trinucleotide polymorphism at the 5' end of the gene encoding the androgen receptor, as used in the Bolduc study (6), has become the standard for measuring XCI skewing (Figure 1B).

The clinical relevance of skewed XCI

Skewing of XCI can reflect or result in biological consequences for females. Because XCI is stable once established, clonal expansion of a somatic cell — as occurs in cancer — results in a cell population with extremely skewed XCI. This is often used to assess tumor clonality (7). For some X-linked diseases there is strong selection in the heterozygous carrier in favor of cells bearing the mutation on the silenced inactive X, and thus, assessment of XCI



Table 1
Different haplotype frequencies among
HapMap populations for *XIST*

<i>XIST</i> haplotype ^A	CEU	YRI	JPT/CHB
T-A-C-T	0.59	0.17	0.07
C-C-C-T	0.16	0.22	0.01
C-A-C-C	0.2	0.09	0.92
C-A-T-T	0.06	0.22	0
C-A-C-T	0	0.30	0

^AHaplotype designation is from four of the five SNPs used in Bolduc et al. study (6) (rs1082089 did not have complete population data) ordered by location on chromosome as rs1620574, rs1794213, rs1009948, and rs1894271). The allele information provided by Bolduc et al. did not explicitly state the order of SNPs; however, an estimated 80% of their subject population was homozygous for an *XIST* haplotype. Data retrieved from HapMap (22); release 21a (NCBI build 35). CEU, Utah (USA) residents with ancestry from northern and western Europe; YRI, Yoruba people from Ibadan, Nigeria; JPT/CHB, Japanese people from Tokyo, Japan, and Han Chinese people from Beijing, China.

skewing in female family members can be suggestive of carrier status (8). In X-linked disorders where XCI skewing is not driven by selection, the extent of stochastic skewing can influence the extent of disease. For example, in the case of Fabry disease — an X-linked recessive inherited lysosomal storage disease — the possibility of therapeutic intervention makes the assessment of XCI skewing of increasing diagnostic value as therapies develop (9). More recently, increases in somatic XCI skewing have been associated with a variety of diagnoses, including premature ovarian failure and recurrent spontaneous abortion, several autoimmune disorders including scleroderma, and some cancers, notably breast cancer (e.g., refs. 10–12). As no causative X-linked locus has yet been identified in such associations, causes of XCI skewing in addition to selection need to be considered (e.g., refs. 10, 13).

Consideration of the sources of skewed XCI

If the assessment of XCI skewing is to be used as a clinical tool, we need to understand the biological sources of skewing. There have now been several large-scale analyses of XCI in an effort to define the basal level of skewing, the largest of which examined skewing in over 1,000 women (14). This new paper from Bolduc

and colleagues (6) provides another large dataset for the literature. There is variability among studies (extreme skewing in newborns ranging from 0.5% to 2.7% of the population examined), some of which might be attributable to differences in methodology, however, the most striking changes in frequency of skewing are seen with patient age and cell type studied.

Much of the skewing seen in adult hematopoietic cells is not observed in newborns. Bolduc et al. observed a doubling of the frequency of extreme skewing in mothers relative to their newborns (6). This increase in skewing seems to become even more pronounced as women age (15). The Bolduc study also analyzed both blood and buccal (epithelial) tissue for skewing (6). They observed a substantial correlation between the two tissues, with blood showing greater skewing in both the neonates and mothers in agreement with previous studies (16, 17). This is an important finding because it suggests that tissues of different germ-lineage origin show similar inactivation patterns. As the tissue(s) affected by an X-linked disorder may be inaccessible to study, it will be important to determine the extent to which accessible tissues (such as blood or buccal samples) reflect the XCI pattern in other tissues. Age-related, acquired XCI skewing can lead to late-onset disease in individuals, as has been reported for X-linked sideroblastic anemia (18). If age-related, acquired XCI skewing occurs in tissues other than blood then late-onset symptoms might be a concern for additional X-linked disorders. Within blood, substantial differences in skewing, particularly in older adults, have been reported for different subpopulations of hematopoietic cells (19), which means that any differences in an individual's immune health or method of sample acquisition that might bias cell representation may contribute to variability between individuals and studies.

A critical question addressed by the Bolduc study was whether there is a genetic component to skewing of XCI (6). Several twin studies have shown a substantial genetic component to acquired or secondary XCI skewing (20, 21). However, there has been limited study of the intriguing question of whether there are primary influences in humans on the choice of which X chromosome to inactivate. To address this issue, Bolduc et al. examined concordance between mother-daughter

pairs for XCI skewing. In both buccal and hematopoietic cells, the authors saw no evidence that neonates with skewed XCI are more likely to have had a mother with skewed XCI. There are considerable challenges to such studies as discussed by the authors. First, much of the skewing observed in the mothers could have been caused by selective pressures and acquired secondarily rather than reflecting an initial bias. Second, the low frequency of skewing in the newborn population means that sample sizes need to be very large to detect a significant heritable effect. Finally, the contribution of the paternal allele is difficult to address since males do not inactivate their only X chromosome. Therefore, drawing an analogy with the murine *Xce*, the authors examined polymorphisms in the *XIST* gene to determine whether there was a correlation between a particular allele or haplotype (combination of alleles) and the prevalence of XCI skewing. Again, no evidence for a genetic component to skewing was observed. Interestingly, however, the French-Canadian population examined in this study was relatively homogeneous for the *XIST* alleles studied, limiting the authors' power to detect a significant effect. There are striking population differences between *XIST* haplotype frequencies (see Table 1; ref. 22), suggesting that studies in other populations (or heterogeneous populations) might reveal a different story.

There are many case reports in the literature of families that seem to have substantial heritable skewing of XCI (for example, refs. 23, 24). Unlike in mice, in which the *Xce* alleles play a critical role in this skewing, such cases may reflect acquired skewing due to selection or very rare mutations related to *XIST* (25). While the population differences for *XIST* suggest we cannot yet close the book on the existence in humans of an *Xce*-like gene, the results from the Bolduc study in this issue of the *JCI* (6) support the hypothesis that the majority of XCI skewing observed in the adult population is acquired secondarily.

Acknowledgments

Work in the authors' laboratories is supported by the Canadian Institutes of Health Research.

Address correspondence to: Carolyn J. Brown, Department of Medical Genetics, University of British Columbia, 2350



Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada. Phone: (604) 822-0908; Fax: (604) 822-5348; E-mail: cbrown@interchange.ubc.ca.

1. Lyon, M.F. 1961. Gene action in the X-chromosome of the mouse (*Mus musculus* L.). *Nature*. **190**:372–373.
2. Migeon, B.R. 2007. *Females are mosaics: X inactivation and sex differences in disease*. Oxford University Press. New York, New York, USA. 296 pp.
3. Cattaneach, B.M., and Williams, C.E. 1972. Evidence of non-random X chromosome activity in the mouse. *Genet. Res.* **19**:229–240.
4. Avner, P., et al. 1998. Molecular correlates of the murine Xce locus. *Genet. Res.* **72**:217–224.
5. Heard, E., and Distech, C.M. 2006. Dosage compensation in mammals: fine-tuning the expression of the X chromosome. *Genes Dev* **20**:1848–1867.
6. Bolduc, V., et al. 2008. No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans. *J. Clin. Invest.* **118**:333–341.
7. Linder, D., and Gartler, S.M. 1965. Glucose-6-phosphate dehydrogenase mosaicism: Utilization as a cell marker in the study of leiomyomas. *Science*. **150**:67–69.
8. Puck, J.M., Nussbaum, R.L., and Conley, M.E. 1987. Carrier detection in X-linked severe combined immunodeficiency based on patterns of X chromosome inactivation. *J. Clin. Invest.* **79**:1395–1400.
9. Dobrovolsky, R., et al. 2005. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. *J. Mol. Med.* **83**:647–654.
10. Bretherick, K., Gair, J., and Robinson, W.P. 2005. The association of skewed X chromosome inactivation with aneuploidy in humans. *Cytogenet. Genome Res.* **111**:260–265.
11. Ozbalkan, Z., et al. 2005. Skewed X chromosome inactivation in blood cells of women with scleroderma. *Arthritis Rheum.* **52**:1564–1570.
12. Kristiansen, M., et al. 2002. High frequency of skewed X inactivation in young breast cancer patients. *J. Med. Genet.* **39**:30–33.
13. Migeon, B.R. 2006. The role of X inactivation and cellular mosaicism in women's health and sex-specific diseases. *JAMA*. **295**:1428–1433.
14. Amos-Landgraf, J.M., et al. 2006. X chromosome inactivation patterns of 1,005 phenotypically unaffected females. *Am. J. Hum. Genet.* **79**:493–499.
15. Hatakeyama, C., et al. 2004. The dynamics of X-inactivation skewing as women age. *Clin. Genet.* **66**:327–332.
16. Sharp, A., Robinson, D., and Jacobs, P. 2000. Age- and tissue-specific variation of X chromosome inactivation ratios in normal women. *Hum. Genet.* **107**:343–349.
17. Knudsen, G.P., et al. 2006. Increased skewing of X chromosome inactivation in Rett syndrome patients and their mothers. *Eur. J. Hum. Genet.* **14**:1189–1194.
18. Cotter, P.D., et al. 1995. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. *J. Clin. Invest.* **96**:2090–2096.
19. Gale, R.E., Fielding, A.K., Harrison, C.N., and Linch, D.C. 1997. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. *Br. J. Haematol.* **98**:512–519.
20. Kristiansen, M., et al. 2005. Twin study of genetic and aging effects on X chromosome inactivation. *Eur. J. Hum. Genet.* **13**:599–606.
21. Vickers, M.A., McLeod, E., Spector, T.D., and Wilson, I.J. 2001. Assessment of mechanism of acquired skewed X inactivation by analysis of twins. *Blood*. **97**:1274–1281.
22. International HapMap Project. <http://www.hapmap.org>.
23. Ropers, H.H., Wienker, T.F., Grimm, T., Schroetter, K., and Bender, K. 1977. Evidence for preferential X-chromosome inactivation in a family with Fabry disease. *Am. J. Hum. Genet.* **29**:361–370.
24. Bicocchi, M.P., et al. 2005. Familial nonrandom inactivation linked to the X inactivation centre in heterozygotes manifesting haemophilia A. *Eur. J. Hum. Genet.* **13**:635–640.
25. Plenge, R.M., et al. 1997. A promoter mutation in the XIST gene in two unrelated families with skewed X-chromosome inactivation. *Nat. Genet.* **17**:353–356.

Blood is thicker than lymph

Mark L. Kahn

Department of Medicine and University of Pennsylvania Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Growth of blood and lymphatic vessels is essential in the developing embryo and in the pathogenesis of human diseases such as cancer, but the signaling pathways that regulate vessel growth and function are not yet well characterized. In this issue of the JCI, studies by Fritz-Six et al. and Ichikawa-Shindo et al. demonstrate that loss of signaling by the adrenomedullin peptide results in embryonic edema and death (see the related articles beginning on pages 40 and 29, respectively). Remarkably, this phenotype is attributed to defects in lymphatic vessels by one group and to defects in blood vessels by the other. In addition to defining what I believe to be a novel angiogenic signaling pathway, these studies demonstrate the intricate molecular, genetic, and physiologic relationships between blood and lymphatic vessels that must be considered by investigators of vascular biology.

Blood and lymphatic vessels: embryonic connections

Mammals have 2 distinct vascular systems: a blood vascular network essential for the delivery of oxygen and nutrients, and a lymphatic vascular network that returns extracellular

fluid and proteins to the blood circulation and coordinates the immune response. These vascular systems form sequentially during embryonic life. The blood vascular system develops first, coordinately with development of the heart and blood to feed the growing embryo. The lymphatic vascular system develops in midgestation as the blood cardiovascular system matures and hemodynamic forces rise (1). Mouse genetic studies have confirmed Florence Sabin's century-old hypothesis that lymphatic vessels arise from venous endothelial cells that exit the cardinal vein and coalesce to form the lymph

sacs, the first lymphatic vascular structures (2, 3). Angiogenic sprouting from the primitive lymph sacs ultimately gives rise to a new vascular network of lymphatic vessels. Blood and lymphatic vessels are often considered as distinct systems with little overlapping function or regulation, but studies of genetically modified mice, and even the origin of human diseases such as Kaposi sarcoma (4, 5), have begun to reveal the strong molecular and physiologic relationships between these vascular entities. In this issue of the JCI, 2 studies of adrenomedullin (AM) signaling identify a developmental link between the blood and lymphatic vascular systems (6, 7).

AM: a pleiotropic regulator of vascular function

AM is a 52-aa peptide, first isolated from a human pheochromocytoma, that is a member of the family of calcitonin gene-related peptides (CGRPs), which is composed of calcitonin, AM, CGRP1 and CHRP2, and amylin. At the time of its discovery AM was noted to be a potent vasodilator (8), and it has subsequently been linked to the regulation of numerous vascular responses,

Nonstandard abbreviations used: AM, adrenomedullin; CALCRL, calcitonin receptor-like receptor; CGRP, calcitonin gene-related peptide; RAMP, receptor activity-modifying protein.

Conflict of interest: The author has declared that no conflict of interest exists.

Citation for this article: *J. Clin. Invest.* **118**:23–26 (2008). doi:10.1172/JCI34485.